-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Photo: Researchers from the Riga Institute of Leuven University and CD3 have developed a super-strong dengue virus inhibitor, which causes a tropical disease called dengue fever
Source: Leuven University-Rob Stevens
Researchers at the KU Leuven Rega Institute and CD3 have developed a powerful inhibitor of dengue virus, which causes the tropical disease dengue fever
Every year, as many as 400 million people are infected with dengue fever, 100 million people get sick, and thousands die
The disease is caused by the dengue virus transmitted by mosquitoes, which is found in almost all (sub)tropical regions, but is particularly severe in Latin America and Asia
There are currently no available antiviral drugs to prevent or treat dengue fever
Stop the "replica of the virus"
Professor Johan Neyts of the Riga Institute of Leuven University explained that this antiviral drug has a unique mechanism
The team and Professor Xavier de Lamballerie (University of Aix-Marseille) demonstrated that this antiviral drug is very effective against all known dengue virus variants
The researchers also tested the inhibitor in mice
Also suitable for prevention
Studies in mice indicate that this inhibitor can also be used for preventive purposes
Prof.
The antiviral drug will be developed in an easy-to-manage formulation that can be optimized for the treatment and prevention of diseases in tropical and subtropical areas where dengue fever is endemic
Interrupt search
Professor Johan Neyts of KU Leuven said that the development of antiviral drugs is a long process
Patrick Chardin of the Center for Drug Design and Discovery added that there are four dengue viruses, and this molecule needs to be equally effective against all four viruses
Since 2013, scientists from Janssen Pharmaceuticals-including Marnix Van lock, Olivia Goethals, and Tim Jonckers-have worked closely with the Leuven University team to accelerate the further development of the chemistry series
Ambitions beyond dengue fever
Leuven University and CD3 also have ambitious plans to fight other viruses
DOI
10.
1038 / s41586-021-03990-6
A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
